PDA

View Full Version : New vaccine - patients stage III or in remission


StephN
06-08-2006, 12:43 PM
Like me some of the others out there have had trouble qualifying for the HER2 vaccine trials (and I am right here in Seattle!). Tried for the peptide trial and had the wrong HLA number. Tried for the DNA based trial and have a positive ANA (inflammation) reponse which disqualified me.

NOW Patty F at the U of W sends me word of yet another vaccine trial. This is not for HER2 specific cancers but has another target so is open to others NOT Her2 positive.

The TROVAX vaccine will begin a phase II study the end of summer. It is not specifically a HER2 target, but works against 5T4, something common to tumors of various origins.
Only thing is :
"This phase II trial is studying how well vaccine therapy works in treating patients with stage IIIB or stage IV breast cancer in remission."

Remission is required for this Trovax study and at this time I qualify. The trial criteria says that bone mets is the only qualifier, but Patty says that has been changed and the patient can have had mets anywhere and qualify. They are updating the wording.
If interested check this link:
http://www.clinicaltrials.gov/ct/show/NCT00227474?order=1 (http://www.clinicaltrials.gov/ct/show/NCT00227474?order=1)

Lolly
06-08-2006, 02:16 PM
THANK YOU Steph; I was telling a Herceptin buddy at my clinic about this trial just yesterday, and will print out the info from the link for her.

Lolly
11-09-2006, 06:59 PM
I spoke with Patty Fintak today, and those interested in this study should contact her to determine if they might qualify. Enrollment should start early next year.

Patty Fintak, Research Coordinator with the Tumor Vaccine Group, UW/Seattle
(206) 543-6620 or e-mail paf3@u.washington.edu

The trial isn't posted on UW's web site yet.
Here's a link from a news bulletin about the group sponsoring the trial, along with a link:

SOUTHWEST ONCOLOGY GROUP TO START PHASE II TRIAL OF OXFORD BIOMEDICA'S TROVAX IN BREAST CANCER

- Regulatory clearance for start of patient recruitment in 120-patient Phase II trial of TroVax in patients with late-stage breast cancer -
http://www.oxfordbiomedica.co.uk/news/2006-ob-18.htm

"Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces that the Southwest Oncology Group (SWOG), a US clinical trials cooperative group, has received regulatory clearance to commence a Phase II trial of Oxford BioMedica’s cancer immunotherapy, TroVax, in patients with late-stage breast cancer..."